TIMI Risk Score for UA/NSTEMI
Thrombolysis in Myocardial Infarction (TIMI) risk score for Unstable Angina and Non-ST-elevation MI. Predicts 14-day risk of death, MI, or urgent revascularisation.
Score interpretation
→ TIMI High Risk (5–7): 14-day adverse event rate ~26–41%. Urgent coronary angiography within 2 hours if haemodynamically unstable; otherwise within 24 hours. Dual antiplatelet therapy; anticoagulation (UFH/enoxaparin); GPIIb/IIIa inhibitor if PCI planned.
→ TIMI Intermediate Risk (3–4): 14-day adverse event rate ~13–19%. Coronary angiography within 24–72 hours; LMWH anticoagulation; dual antiplatelet; cardiology review.
→ TIMI Low Risk (0–2): 14-day adverse event rate ~5%. Conservative management with aspirin; consider stress testing before discharge; cardiology follow-up.
Interpretation bands for the TIMI UA/NSTEMI. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Glyceryl Trinitrate (Sublingual / IV) · Nitrate / Acute Angina
- Isosorbide Mononitrate (Stable Angina) · Nitrate / Stable Angina
- Nicorandil · Stable Angina
- Ranolazine · Refractory Stable Angina
- Colchicine (Pericarditis / Post-MI Inflammation) · Pericarditis / Coronary Inflammation
- Dobutamine (Acute HF / Stress Echo) · Inotrope / Acute Heart Failure
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.